Aperio Group’s Wave Life Sciences WVE Stock Holding History

Aperio Group’s Portfolio WVE Stock Details WVE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-13,491	Closed	-$115K	–	2447
2020 Q3	$115K	Buy	+13,491	New	+$148K	﹤0.01%	2306
2019 Q3	–	Sell	-1,948	Closed	-$51K	–	2770
2019 Q2	$51K	Buy	+1,948	New	+$54.6K	﹤0.01%	2528

Other funds holding WVE

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Aperio Group's WVE Position: Q4 2020 in Review

Aperio Group sold out of Wave Life Sciences (WVE) in Q4 2020, closing a stake of 13,491 shares — an estimated $115K sold.

Aperio Group first reported a position in WVE in Q2 2019 and held it in 2 quarters. The position peaked at $115K in Q3 2020. 108 funds tracked by Wall St. Rank hold WVE as of Q4 2020.

Aperio Group reported no remaining Wave Life Sciences position as of Q4 2020 after selling out during the quarter.
Aperio Group sold 13,491 Wave Life Sciences shares in Q4 2020, an estimated $115K.
Aperio Group first reported a position in Wave Life Sciences in Q2 2019 and held it in 2 quarters.
Aperio Group's Wave Life Sciences position peaked at $115K in Q3 2020.
108 funds tracked by Wall St. Rank held Wave Life Sciences as of Q4 2020.

Based on Aperio Group's 13F filing for Q4 2020, filed 5 Feb 2021.